Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 1;36(4):302-308.
doi: 10.1097/WCO.0000000000001166. Epub 2023 May 29.

Parkinson's disease - current treatment

Ryan Wang  1 , Ludy C Shih  1   2
Affiliations
Review

Parkinson's disease - current treatment

Ryan Wang et al. Curr Opin Neurol. .

Abstract

Purpose of review: The purpose is to review the results and impact of recent studies for current and future treatment of both motor and non-motor symptoms in Parkinson's disease (PD).

Recent findings: New formulations of levodopa further optimize motor fluctuations, allowing for more on-time and less dyskinesia. On demand apomorphine continues to showcase itself as an effective and tolerable tool for treating motor off-periods. Though there are no clear treatment guidelines for PD-related constipation and sleep related disorders, several new agents for these non-motor symptoms show promising preliminary data. Expiratory muscle strength training may represent a useful and cost-effective strategy to alleviate oropharyngeal dysphagia associated with PD. There is evidence to suggest that the use of shorter pulse width and directional deep brain stimulation leads can results in a greater therapeutic window.

Summary: Though no interventions currently exist to significantly modify the disease progression of PD, new studies continue to give insight into optimal symptomatic management. Clinicians should be familiar with expanding the repertoire of tools available to treat the diverse range of symptoms and challenges associated with PD.

PubMed Disclaimer

References

    1. Lampropoulos IC, Malli F, Sinani O, et al. Worldwide trends in mortality related to Parkinson's disease in the period of 1994–2019: analysis of vital registration data from the WHO Mortality Database. Front Neurol 2022; 13:956440.
    1. Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study. Lancet Neurol 2019; 18:459–480.
    1. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet 2021; 397:2284–2303.
    1. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord 2018; 33:1248–1266.
    1. Gray R, Ives N, et al. PD Med Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014; 384:1196–1205.

Publication types

MeSH terms